Trial ID 19151 | Maryland Oncology Hematology Trial ID 19151 – Maryland Oncology Hematology

Trial ID 19151

Trial Information - Phase II

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Disease Specifics: (NSCLC)

Protocol ID: 849-001

Sponsor: Mirati Therapeutics, Inc

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Lung

Investigator

Gaffar MD, Yousuf

Status

OPEN TO ENROLLMENT

Sponsor

Mirati Therapeutics, Inc

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology